macupatide (LY3532226) / Eli Lilly - LARVOL DELTA

A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Eli Lilly and Company

Monotherapy • New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial. (PubMed, Diabetes Obes Metab) - "These findings demonstrate that chronic GIP receptor activation in individuals with T2D leads primarily to increased insulin sensitivity, and that combining GIP and GLP-1 receptor agonism can augment both insulin secretion and insulin sensitivity compared to GLP-1 therapy alone."

Journal • P1 data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=1481 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Sep 2026 ➔ Feb 2028 | Trial primary completion date: Jun 2026 ➔ Sep 2027

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=400 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study of LY3532226 in Participants With Obesity (clinicaltrials.gov) - P1 | N=132 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study of LY3532226 in Participants With Obesity (clinicaltrials.gov) - P1 | N=105 | Active, not recruiting | Sponsor: Eli Lilly and Company | Trial completion date: May 2025 ➔ Nov 2025 | Trial primary completion date: May 2025 ➔ Nov 2025

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study of LY3532226 in Participants With Obesity (clinicaltrials.gov) - P1 | N=105 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Study of LY3532226 in Participants With Obesity (clinicaltrials.gov) - P1 | N=105 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A long-acting glucose dependent insulinotropic polypeptide receptor agonist improves insulin sensitivity and beta cell function in subjects with type 2 diabetes (EASD 2024) - P1 | "Materials and In a 12-week randomized controlled trial, subjects with T2D were enrolled to evaluate the effect of 20 mg LY3532226 weekly (LAGIPRA), 1.5 mg dulaglutide weekly, or LAGIPRA plus dulaglutide weekly on insulin sensitivity and beta-cell function. In patients with T2D, both LAGIPRA and dulaglutide improved body weight and HbA1c, but their effects on insulin sensitivity and beta-cell function differed. LAGIPRA primarily improved insulin sensitivity, whereas dulaglutide had a greater effect on insulin secretion. These effects on insulin sensitivity and secretion were additive when dulaglutide and LAGIPRA were combined."

Clinical • Late-breaking abstract • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3532226 in Participants With Obesity (clinicaltrials.gov) - P1 | N=105 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Genetic Disorders • Obesity

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=90 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=92 | Active, not recruiting | Sponsor: Eli Lilly and Company | Phase classification: P1b ➔ P1

Phase classification • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1b | N=92 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1b | N=92 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1b | N=92 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of LY3532226 in Healthy Participants (clinicaltrials.gov) - P1; N=41; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed

Clinical • Trial completion